Stay updated on Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.

Latest updates to the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check77 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a phase II study on VRP-HER2 immunizations and pembrolizumab for breast cancer, while adding a new version revision and a mention of the study's location.SummaryDifference44%
- Check84 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 12, 2025. However, the deletion of the date March 25, 2025, indicates a potential change in scheduling or availability.SummaryDifference0.2%
Stay in the know with updates to Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.